Comparison of Bone Mineral Density in Women with Polycystic Ovary Syndrome with Healthy Women

Document Type : Original Article (s)

Authors

1 Resident Assistant, Department of Obstetrics and Gynecology, Kurdistan University of Medical Sciences, Sanandaj, Iran

2 Associate Professor, Department of Obstetrics and Gynecology, Kurdistan University of Medical Sciences, Sanandaj, Iran

3 Assistant Professor, Department of Obstetrics and Gynecology, Kurdistan University of Medical Sciences, Sanandaj, Iran

4 PhD Candidate in Epidemiology, Department of Epidemiology and Biostatistics, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

10.48305/jims.v42.i777.0643

Abstract

Background: Polycystic ovary syndrome (PCOS) is a very common and heterogeneous endocrinopathy that affects 5-18% of women. Emerging data suggest that hormonal changes associated with PCOS also affect bone metabolism. This study was conducted to determine bone density in women with PCOS referred to the Besat educational-therapeutic center in Sanandaj, Iran.
Methods: A case-control study was conducted between February 2022 and May 2022, in which 90 women were observed in two groups: a control group and a group diagnosed with polycystic ovary syndrome. The study measured bone density (BMD) of the right lumbar vertebrae (L1-L4), femur neck area, and entire femur using double X-ray absorption.
Findings: According to our study's results, the group suffering from polycystic ovary syndrome showed higher levels of TSH, estradiol, parathyroid hormone, glucose, calcium, and phosphorus than the control group. The level of FSH hormone in the PCOS group was lower than the control group. However, we found no significant difference in bone density between the two groups regarding the lumbar spine, femoral neck, and total femur.
Conclusion: Although the levels of FSH, parathyroid hormone, glucose, calcium, and phosphorus were higher in the control group than in the PCOS group, the bone density of the lumbar vertebra, femoral neck, and total femur was not significant between the two groups.

Highlights

Zahra Roomiani: Google Scholar

Masomeh Rezaie: Google Scholar, PubMed

Bahar Moasses-Ghafari: Google Scholar

Nasrin Soufizadeh: Google Scholar, PubMed

Mohammad Aziz Rasouli: Google Scholar, PubMed

Keywords

Main Subjects

References

  1. Deswal R, Nanda S, Ghalaut VS, Roy PS, Dang AS. Cross-sectional study of the prevalence of polycystic ovary syndrome in rural and urban populations. Int J Gynaecol Obstet 2019; 146(3): 370-9.
  2. To WW, Wong M. A comparison of bone mineral density in oligomenorrhoeic adolescents with polycystic ovaries and normal ovaries. Gynecol Endocrinol 2005; 20(5): 237-42.
  3. Dagogo-Jack S, al-Ali N, Qurttom M. Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 1997; 82(9): 2821-5.
  4. Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril 1999; 72(1): 21-5.
  5. Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002; 77(Suppl 4): S34-41.
  6. Glintborg D, Andersen M, Hagen C, Hermann AP. Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clin Endocrinol (Oxf) 2005 ;62(6):683-91.
  7. Noyan V, Yucel A, Sagsoz N. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 115(2): 200-5.
  8. Yüksel O, Dökmetaş HS, Topcu S, Erselcan T, Sencan M. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab 2001; 19(4): 257-62.
  9. Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabet Med 2000; 17(2): 124-9.
  10. Barrett-Connor E, Kritz-Silverstein D. Does hyperinsulinemia preserve bone? Diabetes Care 1996; 19(12): 1388-92.
  11. Orozco P, Nolla JM. Associations between body morphology and bone mineral density in premenopausal women. Eur J Epidemiol 1997; 13(8): 919-24.
  12. Singla R, Gupta Y, Khemani M, Aggarwal S. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian J Endocrinol Metab 2015; 19(1): 25-9.
  13. Al Kafhage FA, Abbas AN, Al-Masaoodi RA, Hassan S, Al-Shemery MK. The relationship between hormonal levels and hematological parameters in cystic ovarian syndrome. J Med Life 2023; 16(6): 937-40.
  14. Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril 2010; 93(4): 1208-14.
  15. Shan C, Zhu Y-c, Yu J, Zhang Y, Wang Y-y, Lu N, et al. Low Serum 25-Hydroxyvitamin D Levels Are Associated With Hyperandrogenemia in Polycystic Ovary Syndrome: A Cross-Sectional Study. Front Endocrinol (Lausanne) 2022; 13: 894935.
  16. Moini A, Shirzad N, Ahmadzadeh M, Hosseini R, Hosseini L, Sadatmahalleh SJ. Comparison of 25-hydroxyvitamin D and calcium levels between polycystic ovarian syndrome and normal women. Int J Fertil Steril 2015; 9(1): 1-8.
  17. Akbarzadeh M, Naderi T, Dabbaghmanesh MH. The glucose metabolism disorder and dyslipidemia among girls with different phenotype polycystic ovary syndrome. J Res Med Sci 2019; 24: 72.
  18. Dhuper S, Warren MP, Brooks-Gunn J, Fox R. Effects of hormonal status on bone density in adolescent girls. J Clin Endocrinol Metab 1990; 71(5): 1083-8.
  19. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9(6): 505-14.
  20. Golden NH, Carlson JL. The pathophysiology of amenorrhea in the adolescent. Ann N Y Acad Sci 2008; 1135: 163-78.
  21. Weimann E. Gender-related differences in elite gymnasts: the female athlete triad. J Appl Physiol (1985) 2002; 92(5): 2146-52.
  22. Wiksten-Almströmer M, Hirschberg AL, Hagenfeldt K. Reduced bone mineral density in adult women diagnosed with menstrual disorders during adolescence. Acta Obstet Gynecol Scand 2009; 88(5): 543-9.
  23. Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998; 91(1): 12-5.
  24. Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG. Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. T J Clin Endocrinol Metab 2002; 87(7): 3162-8.
  25. Di Carlo C, Shoham Z, MacDougall J, Patel A, Hall ML, Jacobs HS. Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea. Fertil Steril 1992; 57(2): 314-9.
  26. Katulski K, Slawek S, Czyzyk A, Podfigurna-Stopa A, Paczkowska K, Ignaszak N, et al. Bone mineral density in women with polycystic ovary syndrome. J Endocrinol Invest 2014; 37(12): 1219-24.
  27. Karadağ C, Yoldemir T, Gogas Yavuz D. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients. Gynecol Endocrinol 2017; 33(3): 234-7.
  28. Ganie MA, Chakraborty S, Sehgal A, Sreejith M, Kandasamy D, Jana M, et al. Bone mineral density is unaltered in women with polycystic ovary syndrome. Horm Metab Res 2018; 50(10): 754-60.
Journal of Isfahan Medical School
Volume 42, Issue 777
1st Week, October
September and October 2024
Pages 643-650

Files

History

  • Receive Date: 12 May 2024
  • Revise Date: 06 July 2024
  • Accept Date: 17 August 2024

Share

How to cite

Statistics